Published in Thromb Res on June 01, 1976
Standardisation of a simple method for the determination of antithrombin activity. J Clin Pathol (1977) 0.81
Relation between antithrombin III and clinical and serological parameters in systemic lupus erythematosus. J Clin Pathol (1983) 0.77
Heritable alpha 2-macroglobulin deficiency in a patient with arterial thrombosis: alpha 2-macroglobulin deficiency Irvine. J Natl Med Assoc (1984) 0.76
The antiphospholipid-thrombosis syndromes. Fact, fiction, confusion, and controversy. Am J Clin Pathol (1993) 1.93
Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost (1978) 1.22
Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res (1977) 1.13
An update on heparins at the beginning of the new millennium. Semin Thromb Hemost (2000) 0.95
Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost (1985) 0.92
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am (1998) 0.91
Contour detection threshold: repeatability and learning with 'contour cards'. Spat Vis (1999) 0.88
The computation of occluded contours in visual agnosia: Evidence for early computation prior to shape binding and figure-ground coding. Cogn Neuropsychol (2000) 0.85
Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. Ann Thorac Surg (1983) 0.85
Human amyloid-beta1-42 applied in vivo inhibits the fast axonal transport of proteins in the sciatic nerve of rat. Neurosci Lett (2000) 0.84
Histiocytic medullary reticulosis in two Chinese women. West J Med (1974) 0.84
Hereditary and acquired thrombophilia. Part I. Preface. Semin Thromb Hemost (1999) 0.84
Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol (1980) 0.84
In-vivo platelet inhibition by piracetam. Lancet (1979) 0.83
Fibrinolytic activity in acute myocardial infarction. Am J Clin Pathol (1972) 0.83
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol (1999) 0.83
Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost (1976) 0.82
Contribution to the ontogenetic morphology of roots of human teeth. J Dent Res (1967) 0.82
Bleeding times, platelet adhesion, and aspirin. Am J Clin Pathol (1976) 0.82
Laboratory modalities for assessing hemostasis during cardiopulmonary bypass. Semin Thromb Hemost (1976) 0.82
Expression of neurotransmitters and neurotrophins in neurogenic inflammation of the rat retina. Eur J Histochem (2007) 0.82
Thrombotic thrombocytopenic purpura. An extended editorial. Semin Thromb Hemost (1979) 0.81
Anemia of malignancy. Hematol Oncol Clin North Am (1996) 0.81
Glutamate receptor subunits GluR1 and GluR2/3 distribution shows reorganization in the human epileptogenic hippocampus. Eur J Neurosci (1998) 0.81
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost (1999) 0.81
Two motion systems with common and separate pathways for color and luminance. Proc Natl Acad Sci U S A (1993) 0.81
Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica (2005) 0.81
Integrity of lateral and feedbackward connections in visual processing in children with pervasive developmental disorder. Neuropsychologia (2006) 0.81
Clinical use of intrapulmonary heparin. Semin Thromb Hemost (1985) 0.80
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemost (1982) 0.80
Disseminated intravascular coagulation and related syndromes: etiology, pathophysiology, diagnosis, and management. Am J Hematol (1978) 0.79
Contaminants in heparins continue to be unfolded. Int Angiol (2008) 0.79
Antithrombin III and factor VIII in patients with neoplasms. Am J Clin Pathol (1978) 0.79
Clinical relevance of antithrombin III. Semin Thromb Hemost (1982) 0.79
Experimental immune-mediated damage of septal cholinergic neurons. J Neuroimmunol (1997) 0.78
The clinical significance of fibrinogen degradation products. Semin Thromb Hemost (1982) 0.78
[The root-diagram: characteristics of the tilting, divergence, and curvature of tooth roots]. Bull Group Int Rech Sci Stomatol (1966) 0.77
Cholinoceptive neurons without acetylcholinesterase activity and enzyme-positive neurons without cholinergic synaptic innervation are present in the main olfactory bulb of adult rat. Neuroscience (1996) 0.77
Deep vein thrombosis. Diagnosis and management. Med Clin North Am (1994) 0.77
Hemostatic defects induced by cardiopulmonary bypass. Vasc Surg (1976) 0.77
Prothrombin complex concentrate: use in controlling the hemorrhagic diathesis of chronic liver disease. Am J Dig Dis (1975) 0.77
Binding interaction of gamma aminobutyric acid A and B receptors in cell culture. Neuroreport (1991) 0.77
Effect of oral creatine supplementation on jumping and running performance. Int J Sports Med (1997) 0.77
Expressions of amyloid precursor protein, synaptophysin and presenilin-1 in the different areas of the developing cerebellum of rat. Neurochem Int (2000) 0.76
Malaria in drug addicts. JAMA (1971) 0.76
Acquired defects of fibrinolysis associated with thrombosis. Semin Thromb Hemost (1999) 0.76
Motion perception with spatiotemporally matched chromatic and achromatic information reveals a "slow" and a "fast" motion system. Vision Res (1993) 0.76
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clin Hemorheol Microcirc (2007) 0.76
Role of opsonins in clinical response to granulocyte transfusion in granulocytopenic patients. Am J Med (1982) 0.76
Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost (1999) 0.76
Malaria transmission among narcotic addicts. A report of ten cases and review of the literature. Calif Med (1971) 0.75
Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost (1994) 0.75
Cytoplasmic presenilin aggregates in proteasome inhibitor-treated cells. Ann N Y Acad Sci (2000) 0.75
Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost (1999) 0.75
Following the reduction under H2 of supported cobalt catalysts through the L absorption edges. J Synchrotron Radiat (1999) 0.75
Disseminated intravascular coagulation and blood component therapy. Transfusion (1976) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Diath Haemorrh (1975) 0.75
Impact of automation on the quantitation of low molecular weight markers of hemostatic defects. Semin Thromb Hemost (1983) 0.75
Highly stereoselective synthesis and biological properties of nucleoside analogues bearing a spiro inserted oxirane ring. Nucleosides Nucleotides Nucleic Acids (2000) 0.75
The aminoglycoside G418 suppresses muscarinic receptor-activated calcium release in stably transfected murine N1E-115 neuroblastoma cells. Neurosci Lett (1994) 0.75
Fibrinolytic potential in polycythemia rubra vera. Beitr Pathol (1974) 0.75
Disseminated intravascular coagulation: a clinical/laboratory study of 48 patients. Ann N Y Acad Sci (1981) 0.75
Current trends in the development of anticoagulant and antithrombotic drugs. Med Clin North Am (1994) 0.75
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. Semin Thromb Hemost (1984) 0.75
Laboratory diagnosis of antiphospholipid syndromes. Clin Lab Med (1995) 0.75
Daunomycin and fibrinolysis. Thromb Res (1976) 0.75
[A contribution to the genetic study of the topographic relief of the palatal face of upper incisors]. Bull Group Int Rech Sci Stomatol (1969) 0.75
Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations. Semin Thromb Hemost (1999) 0.75
Adriamycin and fibrinolysis. Thromb Res (1976) 0.75
A comparative study of the DuPont antithrombin III and fibrinogen assay systems. Am J Clin Pathol (1985) 0.75
Career planning and development. RNAO News (1984) 0.75
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung. Cancer Treat Rep (1976) 0.75
[A cause of periodontitis: contradiction between morphological root features and jaw function in man]. Quintessenz (1976) 0.75
Surgical hemostasis with a factor XL-containing concentrate. JAMA (1974) 0.75
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management. Clin Appl Thromb Hemost (1999) 0.75
[Prospective comparison between nitrofurantoin and sulphamethoxydiazine in the long-term therapy of children suffering from severe chronic recurrent pyelonephritis]. Dtsch Med Wochenschr (1970) 0.75
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem (1983) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Res (1975) 0.75
Assessment of the results of glottis-dilating operations using lung function tests. Eur Arch Otorhinolaryngol (2002) 0.75
The clinical relevance of plasminogen activator assays. Am J Clin Pathol (1989) 0.75
Synthesis and anti-HIV activity of thymidine analogues bearing a 4'-cyanovinyl group and some derivatives thereof. Nucleosides Nucleotides Nucleic Acids (2001) 0.75
Drug-induced alterations of hemostasis and fibrinolysis. Hematol Oncol Clin North Am (1992) 0.75
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Med Clin North Am (1998) 0.75
Antithrombins and coronary artery disease. Am J Clin Pathol (1984) 0.75
Discrepant AT-III and fibrinogen levels on the DuPont acaTM system. Am J Clin Pathol (1983) 0.75
Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. Ann N Y Acad Sci (1981) 0.75
Fully automated antithrombin-III assays by synthetic substrate on the Multistat III. Am J Clin Pathol (1987) 0.75
[Accumulation of cadmium and lead in the bodies of children and its relation to pollution]. Rev Pediatr Obstet Ginecol Pediatr (1983) 0.75
Clinical implications of molecular markers in hemostasis and thrombosis. Semin Thromb Hemost (1984) 0.75
Blood coagulation as a cybernetic system: control of autoprothrombin C (Factor Xa) formation. Thromb Res (1975) 0.75
Evidence for a new activation phase clotting abnormality in a patient with the Hughes-Stoven syndrome. Beitr Pathol (1974) 0.75
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders. Clin Lab Med (1995) 0.75
Clinical hemostasis practice: the major impact of laboratory automation. Semin Thromb Hemost (1983) 0.75
Role of antithrombin III in clinical management of pulmonary embolization. Am J Med (1984) 0.75
Occlusion of retinal capillaries caused by glial cell proliferation in chronic ocular inflammation. Folia Morphol (Warsz) (2015) 0.75
Alterations of hemostasis associated with cardiopulmonary bypass. Thromb Res (1976) 0.75